|Bid||1.10 x 4300|
|Ask||1.15 x 3200|
|Day's Range||1.05 - 1.14|
|52 Week Range||1.05 - 3.11|
|PE Ratio (TTM)||-0.60|
|Earnings Date||Nov 13, 2017 - Nov 17, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||16.50|
GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation. ARCA Estimates Reporting Top-line Phase 2 B Data in the First Quarter of 2018. WESTMINSTER, Colo., ...
ARCA Estimates Reporting Top-line Phase 2 B Data in the First Quarter of 2018 Gencaro Development Program Has Been Granted Fast Track Designation by U.S. WESTMINSTER, Colo., Aug. 09, 2017-- ARCA biopharma, ...
WESTMINSTER, Colo., Aug. 03, 2017-- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today ...